



## Concurrent Session 3: Incorporating Biospecimen Research into PACHE

*Idhaliz Flores-Caldera, Ph.D.  
Ponce School of Medicine / Moffitt Cancer Center U54  
Partnership*



## Concurrent Session 3: Incorporating Biospecimen Research into PACHE

# Biobanking in Puerto Rico: Challenges and Opportunities



Idhaliz Flores-Caldera, PhD  
Professor, Microbiology and Ob-Gyn  
Ponce Health Sciences University  
Co-Leader Puerto Rico Biobank  
(Co-Leader MCC: Dr. Teresita Muñoz-Antonia)

**2016 PACHE WORKSHOP**

Rockville, Maryland

June 13-14, 2016



## Concurrent Session 3: Incorporating Biospecimen Research into PACHE

### Summary: Challenges & Lessons Learned

Build interest and enthusiasm among hospital administrators and clinical faculty

Clear information about benefits to hospitals, doctors, residency programs

Inventory and data management system

Access to a user-friendly system for coding and keeping track of samples - BMS

Development, harmonization and implementation of SOPs

Multiple meetings, training sessions, retreats to discuss issues and implementation plans

Collection of serum/plasma

Expansion of collection to other hospitals

Clinical data abstraction, Tx outcomes



Additional personnel and resources needed

Increasing tissue usage

Advertisement of resources and of distribution protocol, assess investigator-driven needs

Sustainability


Grants, other initiatives, institutional commitment



## Concurrent Session 3: Incorporating Biospecimen Research into PACHE

### Summary: Opportunities

- Opportunities for research in a ***unique population*** underrepresented in other cohorts - with ***admixture data***.
- Opportunities to teach about biobanking and research to ***doctors in training*** and the ***community***.
- Opportunities for collaboration via development of ***shared resources*** (e.g., breast, colon and lung TMA)
- Last but not least....the PRBB impacts all levels of the Partnership



National Cancer Institute  
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
National Institutes of Health

## Biorepositories and Biospecimen Research Branch (BBRB)

# NCI Resources for Biobanking

Helen M. Moore

Biorepositories and Biospecimen Research Branch

Cancer Diagnosis Program, DCTD

Partnership to Advance Cancer Health Equity Investigators Meeting

June 13, 2016



## Concurrent Session 3: Incorporating Biospecimen Research into PACHE

### BBRB Mission

To provide leadership, tools, resources, and policies in biobanking for the global biomedical research community, to enable translational research and precision medicine for patients.

### Improving Biospecimen Processes is Essential to Enable Better Research, Clinical Trials, and Molecular Medicine

- **Challenges:**
  - Variability of Biospecimen Collection
  - Molecular Integrity of biospecimens
  - Sustainability
- **Solutions:**
  - The NCI Best Practices for Biospecimen Resources
  - Biospecimen Research Database (BRD)
  - Online tool: Biobank Economic Modeling Tool (BEMT)

<http://biospecimens.cancer.gov>

<https://bemt.nci.nih.gov/bemt/public/index>

<https://brd.nci.nih.gov/brd/>



## Concurrent Session 3: Incorporating Biospecimen Research into PACHE

# NCI Resources for Biobanking

**BRISQ:** publication standards for studies utilizing biospecimens

- Goal: improve research reproducibility
- International project
- Integration continuing (e.g. inclusion in *Nature* and *Science Translational Medicine* instructions to authors)

### **BBRB Patient Brochure**

- Comprehensive patient education brochures on the importance of specimen donation
- Available in English and Spanish



## Concurrent Session 3: Incorporating Biospecimen Research into PACHE



**Science** : A representation of how variation in the human genome affects gene expression among individuals and tissues. Colors and shapes show variations between people and within individuals.





## Concurrent Session 3: Incorporating Biospecimen Research into PACHE

### **PAR-16-166: Integrating biospecimen science approaches into clinical assay development**

- Applied biospecimen science research to address the convergence of:
  - Emerging clinical biomarker assays in clinical trials
  - New diagnostics challenges
    - FNA, Core Biopsies, Lung Aspirates for Molecular Testing
    - New analysis technologies applied to clinical samples (RNAseq, WES, multiplex IHC, proteomics)
- *Biopsy material of sufficient quality is critical for iterative testing to support therapeutic regimens and testing for recurrence of disease*